<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_fjtYjGp">Dynamic Trends and Underlying Factors of COVID-19 Vaccine Booster Hesitancy in Adults: Cross-Sectional Observational Study</title>
				<funder ref="#_qHecYkB">
					<orgName type="full">National Social Science Fund of China</orgName>
					<orgName type="abbreviated">NSSFC</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100012456</idno>
				</funder>
				<funder ref="#_EP5cmwn">
					<orgName type="full">2023 Graduate Independent Innovation Project of Zhengzhou University</orgName>
				</funder>
				<funder ref="#_aBqqSPx">
					<orgName type="full">Henan Provincial University Philosophy and Social Science Innovation Talent Support Plan</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Jian</forename><surname>Wu</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Health Management , College of Public Health , Zhengzhou University , Zhengzhou , Henan , China</note>
								<orgName type="department" key="dep1">Department of Health Management</orgName>
								<orgName type="department" key="dep2">College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<region>Henan</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment , Zhengzhou , China</note>
								<orgName type="department">Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Mingze</forename><surname>Ma</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Health Management , College of Public Health , Zhengzhou University , Zhengzhou , Henan , China</note>
								<orgName type="department" key="dep1">Department of Health Management</orgName>
								<orgName type="department" key="dep2">College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<region>Henan</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment , Zhengzhou , China</note>
								<orgName type="department">Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Quanman</forename><surname>Li</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Health Management , College of Public Health , Zhengzhou University , Zhengzhou , Henan , China</note>
								<orgName type="department" key="dep1">Department of Health Management</orgName>
								<orgName type="department" key="dep2">College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<region>Henan</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment , Zhengzhou , China</note>
								<orgName type="department">Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Xinghong</forename><surname>Guo</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Health Management , College of Public Health , Zhengzhou University , Zhengzhou , Henan , China</note>
								<orgName type="department" key="dep1">Department of Health Management</orgName>
								<orgName type="department" key="dep2">College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<region>Henan</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment , Zhengzhou , China</note>
								<orgName type="department">Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Clifford</forename><surname>Silver Tarimo</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Health Management , College of Public Health , Zhengzhou University , Zhengzhou , Henan , China</note>
								<orgName type="department" key="dep1">Department of Health Management</orgName>
								<orgName type="department" key="dep2">College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<region>Henan</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Science and Laboratory Technology , Dar es Salaam Institute of Technology , Dar es Salaam , United Republic of Tanzania</note>
								<orgName type="department">Department of Science and Laboratory Technology</orgName>
								<orgName type="institution">Dar es Salaam Institute of Technology</orgName>
								<address>
									<settlement>Dar es Salaam</settlement>
									<country>United Republic of Tanzania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Shiyu</forename><surname>Jia</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment , Zhengzhou , China</note>
								<orgName type="department">Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Xue</forename><surname>Zhou</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Health Management , College of Public Health , Zhengzhou University , Zhengzhou , Henan , China</note>
								<orgName type="department" key="dep1">Department of Health Management</orgName>
								<orgName type="department" key="dep2">College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<region>Henan</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Public Utilities Management , College of Health Management , Mudanjiang Medical University , Hei Longjiang , China</note>
								<orgName type="department" key="dep1">Department of Public Utilities Management</orgName>
								<orgName type="department" key="dep2">College of Health Management</orgName>
								<orgName type="institution">Mudanjiang Medical University</orgName>
								<address>
									<settlement>Hei Longjiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Meiyun</forename><surname>Wang</surname></persName>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Henan Provincial People&apos;s Hospital , Zhengzhou University , Zhengzhou , China</note>
								<orgName type="department">Henan Provincial People&apos;s Hospital</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Jianqin</forename><surname>Gu</surname></persName>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> School of Medicine , Southern University of Science and Technology , Shenzhen , China</note>
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">Southern University of Science and Technology</orgName>
								<address>
									<settlement>Shenzhen</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Yudong</forename><surname>Miao</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Health Management , College of Public Health , Zhengzhou University , Zhengzhou , Henan , China</note>
								<orgName type="department" key="dep1">Department of Health Management</orgName>
								<orgName type="department" key="dep2">College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<region>Henan</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment , Zhengzhou , China</note>
								<orgName type="department">Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Prof</roleName><forename type="first">Beizhu</forename><surname>Ye</surname></persName>
							<email>yebeizhu@zzu.edu.cn</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Health Management , College of Public Health , Zhengzhou University , Zhengzhou , Henan , China</note>
								<orgName type="department" key="dep1">Department of Health Management</orgName>
								<orgName type="department" key="dep2">College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<region>Henan</region>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment , Zhengzhou , China</note>
								<orgName type="department">Henan Province Engineering Research Center of Health Economy &amp; Health Technology Assessment</orgName>
								<address>
									<settlement>Zhengzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<note type="raw_affiliation">Department of Health Management College of Public Health Zhengzhou University No. 100 , Science Avenue , Gaoxin District Zhengzhou , Henan , 450001 China</note>
								<orgName type="department">Department of Health Management College of Public Health</orgName>
								<orgName type="institution">Zhengzhou University No</orgName>
								<address>
									<addrLine>100 Science Avenue Gaoxin District Zhengzhou</addrLine>
									<postCode>450001</postCode>
									<settlement>Henan</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_Bd6p8Nn">Dynamic Trends and Underlying Factors of COVID-19 Vaccine Booster Hesitancy in Adults: Cross-Sectional Observational Study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">0040B47D373897E2DB266EF784B9681B</idno>
					<idno type="DOI">10.2196/44822</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T13:37+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_86AJyKk">vaccine hesitancy</term>
					<term xml:id="_dan6NAF">COVID-19 booster vaccination</term>
					<term xml:id="_gRmt67S">influencing factors</term>
					<term xml:id="_AXXePGN">China</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_gFyaMBB"><p xml:id="_v64VfAu"><s xml:id="_VGt7VUN">Background: COVID-19 vaccine hesitancy reduces vaccination rates, which is detrimental to building herd immunity and halting the spread of COVID-19 and its variations.</s><s xml:id="_WgvyAJX">Most researches have simply identified the reasons affecting COVID-19 vaccination reluctance without delving into its dynamics, which makes forecasting future trends difficult.</s></p><p xml:id="_mRQkp4v"><s xml:id="_6PxhcJg">Objective: This study aimed to examine the current COVID-19 vaccine booster hesitancy rate in Chinese adults as well as the dynamics of vaccine hesitancy and its influencing factors.</s><s xml:id="_FMut86T">The results of this study will have practical implications for policy responses in mainland China, and effective COVID-19 booster vaccination in specific populations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_baCeR5d">Methods:</head><p xml:id="_cbmbgnj"><s xml:id="_8RYhPWf">The web-based survey was completed by creating questionnaires and using a stratified random sampling method to collect information from adults (≥18 years old) among 2556 households in 4 geographical regions of China.</s><s xml:id="_Pbz3y9j">We collected sociodemographic information, health status, awareness of COVID-19 and its vaccine, self-perceptions, trust in medical staff and vaccine developers, and so on.</s><s xml:id="_wPEkzjX">The odds ratios and 95% CI for the statistical associations were estimated using logistic regression models.</s></p><p xml:id="_4SqjZkK"><s xml:id="_rqsyNfE">Results: Overall, 6659 participants (females: n=3540, 53.2%; males: n=3119, 46.8%) responded.</s><s xml:id="_7YBuAKk">In total, 533 (8%; 95% CI 7.4%-8.7%)</s><s xml:id="_QH4e6WA">participants presented a clear hesitancy in receiving the COVID-19 booster vaccination, while 736 (11.1%; 95% CI 10.3%-11.8%)</s><s xml:id="_qrvmX3H">expressed hesitancy in regular booster vaccination.</s><s xml:id="_SJfgajX">A higher prevalence of vaccine hesitancy in both booster vaccination and regular booster vaccination was observed among participants with a history of allergies, experiencing chronic disease, lower levels of public health prevention measures or susceptibility or benefits or self-efficiency, higher levels of severity or barriers, and lower trust in both medical staff and vaccine developers (P&lt;.05).</s><s xml:id="_DNKs4xD">The females and participants with higher education levels, higher levels of barriers, lower levels of susceptibility, and lower trust in vaccine developers preferred to have attitudinal changes from acceptance to hesitancy, while people with higher education levels, lower self-report health conditions, experiencing chronic disease, history of allergies, and lower trust in medical staff and developers were all positively associated with constant COVID-19 booster hesitancy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MZ3TECZ">Conclusions:</head><p xml:id="_j7XCEaw"><s xml:id="_9SgAqAc">The prevalence of COVID-19 vaccine booster hesitancy is not high in mainland China.</s><s xml:id="_HunjdbP">However, there is a slight increment in hesitancy on regular booster vaccination.</s><s xml:id="_6g8SYYh">Conducting targeted information guidance for people with higher education</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_DVaUmm7">Introduction</head><p xml:id="_vzCfJyg"><s xml:id="_ErmVSAr">Vaccinating a sufficient proportion of the population against COVID-19 is one of the most effective methods for achieving "herd immunity," lowering morbidity, and increasing population survival.</s><s xml:id="_J8fvNES">It is also the most cost-effective and straightforward intervention to prevent the COVID-19 pandemic <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s xml:id="_AgT4e38">Prevention of the COVID-19 virus and its variants through COVID-19 vaccination can confer benefits related to morbidity and mortality <ref type="bibr" target="#b2">[3]</ref>, mainly including the protection of immunocompromised populations such as infants, young children, and the elderly <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s xml:id="_XzsqSMk">According to the latest reports from the World Health Organization (WHO), two-thirds of the world's population is vaccinated, including 75% of health workers and older people.</s><s xml:id="_FEE4vXQ">However, there are still wide disparities in vaccination rates <ref type="bibr" target="#b5">[6]</ref>.</s><s xml:id="_jB9fZdj">The COVID-19 booster vaccination is an important tool for consolidating herd immunity and responding to the COVID-19 pandemic and deaths <ref type="bibr" target="#b6">[7]</ref>, and receiving the COVID-19 booster vaccine is essential to achieve adequate immunization coverage to control the global pandemic <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s xml:id="_2WhG9DA">Understanding people's attitudes to COVID-19 booster vaccination aids in developing COVID-19 booster vaccination plans, which ensure the consolidation of herd immunity and minimize health inequalities.</s></p><p xml:id="_7VpKuRK"><s xml:id="_xggUZ2v">Since the global outbreak of the COVID-19 epidemic, several vaccines have been developed, such as inactivated vaccines, live-attenuated vaccines adenovirus vector vaccines, and recombinant protein vaccines <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s xml:id="_pEcEg98">Although these multiple vaccines are considered safe and effective <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>, and countries around the world are increasing the supply of vaccines, waiving vaccination fees <ref type="bibr" target="#b11">[12]</ref>, and actively promoting the COVID-19 booster vaccination, there are still concerns about vaccine hesitancy, which affects the vaccination rates of COVID-19 vaccines as well as booster vaccination.</s><s xml:id="_BWAyM6M">This situation may not be helpful to bolster herd immunity in order to prevent the further spread of COVID-19 and its variations.</s><s xml:id="_XNaAUwV">According to the WHO, "Vaccine hesitancy" has been considered as one of the top 10 public health problems across the world <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref>.</s><s xml:id="_Fz2P2US">It refers to the delay or refusal to receive safe vaccination services, which can accompany the use of vaccines <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>.</s><s xml:id="_rQEENkY">The danger of vaccine hesitancy is that it can lead to immunization of populations below the herd immunity threshold and ultimately fail to protect the populations.</s><s xml:id="_Dx6QF3X">This is particularly true for people whose immunity is very weak to be vaccinated, such as infants, the elderly, or patients with serious illnesses, who are the first to be exposed to infectious diseases if the herd immunity barrier is breached <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b17">18]</ref>.</s><s xml:id="_fDGGQdy">The COVID-19 vaccine booster hesitancy is a type of vaccine hesitancy and is a continuation of people's hesitancy about the COVID-19 vaccine.</s><s xml:id="_m7P5vf8">Therefore, what factors influence people's hesitancy to receive the COVID-19 booster vaccine?</s><s xml:id="_adHcx4T">An in-depth study of this issue would be of great relevance in guiding the next phase of the COVID-19 booster vaccination program.</s></p><p xml:id="_bvSCnnc"><s xml:id="_wvpnB7D">The reasons for vaccine hesitancy are thought to be complex and case specific.</s><s xml:id="_rraMy4A">The existing literature cites concern about COVID-19 vaccine safety and efficacy, vaccination accessibility, the severity of the regional epidemic, experience with routine vaccination, and guardians' willingness to vaccinate their children as the primary reasons for hesitancy.</s><s xml:id="_jE6vDxT">For example, in a study of Canadians, individuals with vaccine hesitancy had a higher prevalence of being concerned about vaccine side effects <ref type="bibr" target="#b18">[19]</ref>.</s><s xml:id="_w95uZte">The antecedents of vaccine hesitancy range from a lack of knowledge and awareness to culturally rooted reservations <ref type="bibr" target="#b19">[20]</ref>.</s><s xml:id="_WbuPspv">The most commonly reported reasons parents chose not to vaccinate their child against COVID-19 were concerns about long-term adverse side effects and a negative reaction <ref type="bibr" target="#b20">[21]</ref>.</s><s xml:id="_2MRVHpp">At the same time, concern about side effects is also the most common reason for COVID-19 vaccine hesitancy in low-and middle-income countries <ref type="bibr" target="#b2">[3]</ref>.</s><s xml:id="_QsRAfSy">In addition, misinformation and disinformation can substantially result in vaccine hesitancy <ref type="bibr" target="#b21">[22]</ref> and might influence the vaccine advice of health care providers <ref type="bibr" target="#b22">[23]</ref>.</s><s xml:id="_KxESmH8">These factors will probably influence people's hesitancy about the COVID-19 booster vaccination.</s></p><p xml:id="_txNszPz"><s xml:id="_kKMKy7D">Understanding local barriers to vaccination and concerns about vaccination is critical to developing tailored interventions <ref type="bibr" target="#b23">[24]</ref>.</s><s xml:id="_v5ufJA2">The current basic vaccination rate of COVID-19 vaccine in China exceeds 89% <ref type="bibr" target="#b11">[12]</ref>, which is probably one of the leading countries in the world not only because of its large population but also its extensive exchanges and closer cooperation with other regions <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s xml:id="_gdba255">However, the coverage of booster vaccination in China is not widespread, which is still a significant gap compared with the basic vaccination rate.</s><s xml:id="_DWpZy6c">Furthermore, compared to other countries around the world, the epidemic prevention and control policies in mainland China are adequate, and vaccines are supplied for free and in sufficient quantities <ref type="bibr" target="#b26">[27]</ref>, but the problem of vaccine hesitancy remains unresolved.</s><s xml:id="_HRCX5Jb">Focusing on the problem of vaccine hesitancy in COVID-19 booster vaccination in mainland China will be highly representative.</s><s xml:id="_5aMAhvU">The existing research on booster vaccination hesitancy is limited, and hence, we designed a multicenter study focusing on COVID-19 vaccine booster vaccination and regular booster vaccination in mainland China.</s><s xml:id="_JfEau2P">This study aimed to understand the current COVID-19 vaccine hesitancy in booster vaccination of the Chinese population and analyze the dynamic trend of vaccine hesitancy as well as its influencing factors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_BY8ecXP">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fx8mdQa">Procedures and Participants</head><p xml:id="_bq2aGcb"><s xml:id="_GXACZfW">From June 29, 2022, to July 2, 2022, we used a self-designed questionnaire to perform a preliminary survey by recruiting web-based volunteers.</s><s xml:id="_DkRkUCF">We conducted The Dynamic Evolution of COVID-19 Vaccination Study, a national, multicenter, observational household tracking survey from China using a stratified random sampling method.</s><s xml:id="_dm766s5">Eastern, Central, Western, and Northeast geographical regions within mainland China were selected to form the sample for this study.</s><s xml:id="_mmA2wPy">Therefore, 4 cities were selected from the Eastern (Changzhou and Jiangsu), Central (Zhengzhou, Henan), Western (Xi'ning and Qinghai), and Northeast (Mudanjiang and Heilongjiang) regions.</s></p><p xml:id="_ewsGwWd"><s xml:id="_rdDqphC">We calculated the minimum sample size of each region according to the population proportion of China's Seventh National Population Census.</s><s xml:id="_C4eM2kj">In each province, the sample size of urban and rural areas was determined according to the proportion of population in the Seventh National Population Census, more than 2 cities and 2 rural areas were randomly selected for sampling.</s><s xml:id="_xBAN686">For all of the cities and families in the sample, coding was carried out followed by random sampling.</s><s xml:id="_49Xs7X4">Finally, all members of the selected family have been involved in this survey (age≥18 years) and completed the web-based or offline questionnaire with the assistance of the investigators.</s><s xml:id="_tGsvGnr">A total of 2556 households from 4 geographic regions of China were enrolled in the survey.</s></p><p xml:id="_33TBDHd"><s xml:id="_d4j3Vk9">The study was designed as a 4-stage survey.</s><s xml:id="_WM9haAM">For the first stage, we conducted the survey from August 3, 2022, to August 14, 2022.</s><s xml:id="_tJFfBCu">Data collection is still ongoing for the second, third, and fourth stages.</s><s xml:id="_FynQNMa">Here, we describe the results from the first stage of the study only.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jwAsTuy">Ethics Approval</head><p xml:id="_BBCdyzF"><s xml:id="_nUdEba3">Participants were informed of the benefits and risks of participating in this study, and they provided informed consent.</s><s xml:id="_7ADGVe6">All data were used merely for research purposes.</s><s xml:id="_wWG9sCe">This study was approved by the Life Science Ethics Review Committee of Zhengzhou University (2021-01-12-05).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_d4z4da7">Questionnaire Design and Data Collection</head><p xml:id="_Xq7JKvk"><s xml:id="_cTTP7vN">Web-based questionnaires were designed to collect data through a survey conducted through the Wenjuanxing platform.</s><s xml:id="_zV8BXcU">We also conducted a face-to-face interview with participants who cannot use a smartphone.</s><s xml:id="_nXJGmR2">The questionnaire covered five thematic areas: (1) sociodemographic characteristics: age, gender, nation, religion, marital status, educational status, subjective social status in China or community, smoking status, drinking status, and physical activity; (2) health conditions: chronic disease, the history of allergies, self-report health condition (measured by EuroQol 5 Dimensions Questionnaire <ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref>); (3) perception of COVID-19 and its vaccine: public health prevention measures, awareness of COVID-19 vaccines, the channel of accessing information, the way of accessing information, the risk of COVID-19 infection, the history of COVID-19 infection, the convenience of vaccination, and the uptake of COVID-19 vaccine; (4) self-perception (Kaiser-Meyer-Olkin=0.796):</s><s xml:id="_qVtZxJz">perceived severity (Cronbach α=.879), perceived susceptibility (Cronbach α=.865), perceived benefits (Cronbach α=.907), perceived barriers (Cronbach α=.927), and self-efficiency (Cronbach α=.913; Kaiser-Meyer-Olkin=0.886); and (5) trust in medical staff and developers.</s><s xml:id="_JATbumU">All questionnaires are shown in Multimedia Appendix 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7JbBhtV">Assessments</head><p xml:id="_2QBmkwJ"><s xml:id="_vhgDcY6">Questionnaires with abnormal answers (contradictions and inconsistencies, eg, inconsistency or contradictions of sex) were excluded.</s><s xml:id="_28rQtRz">In addition, we also excluded the participants who spent less than 5 minutes completing this questionnaire.</s><s xml:id="_URGyDrB">Moreover, the remaining questionnaires were carefully reviewed by trained staff, and finally, 6659 questionnaires were deemed eligible for inclusion.</s><s xml:id="_CvGByCE">The flowchart of participants is shown in Figure <ref type="figure" target="#fig_0">1</ref>.</s></p><p xml:id="_Fn7yVkn"><s xml:id="_XggZVxv">The primary outcome was COVID-19 vaccine hesitancy in both booster and regular booster vaccination, assessed by asking participants "Are you willing to get a booster vaccination of the COVID-19 vaccine?" and "In the future, would you like to get a booster vaccination of the COVID-19 vaccine?" Participants could choose 1 response from the options "(1) willing," "(2) hesitant or delayed," "(3) refused," and "(4) do not interested" from the 2 questions.</s><s xml:id="_CxKx8MM">According to the definition of vaccine hesitancy, option 1 was regarded as "acceptance," and options 2 and 3 were merged into "hesitancy."</s><s xml:id="_yxHetRe">In addition to this, participants were excluded if they selected the option "do not interested" (n=122).</s></p><p xml:id="_WdskVrC"><s xml:id="_GuQtS7j">A booster vaccination is a shot that is given after a period of time (which may be 6 months or more) after a population has completed a standard immunization program, and due to the gradual decay of antibodies in the body, the specific immunity in the body needs to be boosted with another booster vaccination.</s><s xml:id="_KwNKF5B">Regular booster vaccinations are administered after a period of booster vaccination to strengthen the immune system.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4WfMnCj">Statistical Analysis</head><p xml:id="_j4UgWTP"><s xml:id="_pzh8fkD">Chi-square tests were used to test differences in vaccine hesitancy between groups.</s><s xml:id="_3GrEK9s">Binary logistic regression analyses were carried out to examine factors associated with COVID-19 vaccine hesitancy in both booster and regular booster vaccination.</s><s xml:id="_4XSfyEt">A sensitivity analysis was performed by excluding the participants aged ≥80 years to test the robustness of results and assess the source of uncertainty.</s><s xml:id="_K7r7Ws6">In stratified multistage sampling, post hoc stratification was used to weight the sample and the corresponding variables so that the sample's estimate of the total was unbiased.</s><s xml:id="_yKX2FWN">Odds ratios, 95% CI, and P values were calculated for each independent variable.</s><s xml:id="_Cxcum9H">All statistical analyses were carried out using SPSS (version 21.0;</s><s xml:id="_2rnHb2a">IBM Corp) and STATA (version 16.0; StataCorp).</s><s xml:id="_998uNce">Differences were regarded as statistically significant if P values were less than .05.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EBjTSDz">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sdTAqZ3">Characteristics of COVID-19 Vaccine Hesitancy in Booster Vaccination</head><p xml:id="_ekvewmy"><s xml:id="_CjszVXx">Among the 8002 participants who completed the questionnaire, a total of 1343 participants who did not meet the inclusion criteria were subsequently excluded.</s><s xml:id="_md7zErE">Importantly, no statistically significant differences were found between the final 6659 participants included in the analysis and the overall sample of 8002 (P&gt;.05) (Multimedia Appendix 2).</s><s xml:id="_cQ8uVV7">The sociodemographic characteristics, awareness of COVID-19 vaccine, trust in the health care system as well as COVID-19 vaccine hesitancy in booster vaccination and regular booster vaccination of all study participants are displayed in Table <ref type="table" target="#tab_0">1</ref>.</s><s xml:id="_fG6XDHb">Overall, 533 adults (8%; 95% CI 7.4%-8.7%)</s><s xml:id="_kyse8HY">showed a clear COVID-19 vaccine hesitancy in booster vaccination, while 6126 adults (92%; 95% CI 90.3%-94.2%)</s><s xml:id="_HR2VXwy">indicated that they were willing to vaccinate.</s><s xml:id="_aJdRkjp">Meanwhile, 736 participants (11.1%; 95% CI 10.3%-11.8%)</s><s xml:id="_ZbRf4AU">expressed their hesitancy about regular booster vaccination of COVID-19 vaccine.</s><s xml:id="_V7H3nQZ">Furthermore, we can see clearly that the participants of all ages are evenly distributed, the proportion of female participants (53.2%) is more than male (46.8%), and most of the participants (87.5%) were married.</s></p><p xml:id="_QR5vcBS"><s xml:id="_nwtDUM2">A higher prevalence of vaccine hesitancy in both booster vaccination and regular booster vaccination was observed among participants with a history of allergies, experiencing chronic disease, lower levels of public health prevention measures or susceptibility or benefits or self-efficiency, higher levels of severity or barriers, and lower trust in both medical staff and vaccine developers (all P&lt;.05; Figure <ref type="figure" target="#fig_1">2</ref>).</s><s xml:id="_t7VhHzY">b Row percentages derived from the total number in the corresponding row.</s></p><p xml:id="_hzp6maD"><s xml:id="_dgwQMDJ">c Levels 1-4 indicate progressively higher degrees.</s><s xml:id="_tDM54kK">The higher the degree, the higher level of social status in China or community, the better the self-assessment of health status, the more awareness of COVID-19 vaccine, the more severe or more barriers, the greater the susceptibility or benefits, the higher the self-efficacy and the more trust in medical staff and developers.</s><s xml:id="_Qqs74A7">d EQ-5D: EuroQol 5 dimensions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YHG7eMG">Factors Associated With COVID-19 Vaccine Hesitancy in Booster Vaccination</head><p xml:id="_RKwcc7x"><s xml:id="_gyrgK4v">In the binary logistic regression model, subjective social status in China or community, chronic disease, history of allergies, drinking status, physical activity, public health prevention measures, awareness of COVID-19 vaccines, severity, susceptibility, benefits, barriers, self-efficiency, and trust in medical staff or developers were found to be all independently associated with COVID-19 vaccine hesitancy in both booster vaccination and regular booster vaccination (all P&lt;.05).</s></p><p xml:id="_ZbkFSXk"><s xml:id="_TbpQqxd">After adjusting for potential confounders, we found that unmarried, experiencing chronic disease, history of allergies, low level of physical activity, lower level of public health prevention measures or susceptibility or benefits or self-efficiency, higher level of severity or barriers, and lower trust in medical staff or developers were all positively associated with COVID-19 vaccine hesitancy in booster vaccination (all P&lt;.05).</s><s xml:id="_V88ftxA">Meanwhile, we observed that participants who were female, with higher educational level, higher level of subjective social status in community, experiencing chronic disease, history of allergies, lower level of public health prevention measures or susceptibility or benefits or self-efficiency, higher level of severity or barriers, lower trust in both medical staff and developers were all positively associated with COVID-19 vaccine hesitancy in regular booster vaccination after adjusting for potential confounders (all P&lt;.05).</s><s xml:id="_yGu43Mx">Detailed results are all shown in Figure <ref type="figure" target="#fig_1">2</ref> and Multimedia Appendix 3.</s></p><p xml:id="_n9bVMMk"><s xml:id="_cczNHm7">In particular, participants with higher levels of education and lower levels of trust in medical staff or developers showed stronger COVID-19 vaccine hesitancy and higher rates of hesitancy at the following regular booster vaccination.</s><s xml:id="_wzE2RRb">The same trend could be observed in participants with a history of vaccination allergy and those with chronic disease (Figure <ref type="figure" target="#fig_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_us7j5kf">Dynamic Fluctuations of COVID-19 Vaccine Hesitancy in Booster Vaccination</head><p xml:id="_tZS48kh"><s xml:id="_BQr9W2H">The COVID-19 vaccine hesitancy rate among Chinese residents shows a trend of raising, which was from 8% (533/6659) to 11.1% (736/6659) between the booster vaccination and regular booster vaccination.</s><s xml:id="_bqnEwvk">In addition, some participants' attitudes toward COVID-19 vaccine booster vaccination were shown to change.</s><s xml:id="_jGk3usW">There were 5870 and 480 participants who remained vaccinated and hesitant about routine booster vaccination respectively, while there were still 256 participants who would switch from acceptance to hesitancy.</s></p><p xml:id="_u4FTgCA"><s xml:id="_fPUMNCE">Multimedia Appendix 4 lists 4 attitudinal changes toward COVID-19 booster vaccination, such as acceptance to acceptance, acceptance to hesitancy (ATH), hesitancy to acceptance, and hesitancy to hesitancy (HTH).</s><s xml:id="_gv7y6xn">The results demonstrated that participants who were female, with higher educational level, higher level of barriers, lower level of susceptibility or self-efficiency, and lower trust in developers were positively associated with ATH (all P&lt;.05).</s><s xml:id="_XUVmesb">Participants with higher levels of physical activity and self-efficiency as well as not experiencing chronic disease expressed their willingness from hesitancy to acceptance (all P&lt;.001).</s><s xml:id="_QMzm8P2">Furthermore, participants who had higher educational level, lower self-report health condition, having from chronic disease, history of allergies, lower level of public health prevention measures or susceptibility or benefits or self-efficiency, higher level of barriers, lower trust in both medical staff and developers were all positively associated with HTH after adjusting for potential confounders (all P&lt;.05).</s><s xml:id="_BD3Gq7K">Detailed results are all presented in Figures <ref type="figure">4</ref> and <ref type="figure">5</ref> JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 10 <ref type="url" target="https://publichealth.jmir.org/2023/1/e44822">https://publichealth.jmir.org/2023/1/e44822</ref></s><s xml:id="_sxb9PS8">(page number not for citation purposes) Wu et al JMIR PUBLIC HEALTH AND SURVEILLANCE XSL • FO RenderX Figure 5. Relevant influences on hesitancy to acceptance and hesitancy to hesitancy for all participants.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NhjQXHZ">Sensitivity Analysis</head><p xml:id="_k8wkSCK"><s xml:id="_XSSnr36">In sensitivity analyses, the exclusion of participants aged &gt;80 years did not significantly alter the outcome of COVID-19 vaccine hesitancy.</s><s xml:id="_YpQCGRC">Effect estimates for the primary outcome remained similar (Multimedia Appendix 5).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fJJ4ADV">Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rsz9dQy">Principal Findings</head><p xml:id="_BRKstPA"><s xml:id="_rPaWZ5N">This study focused on the hesitancy rate of COVID-19 vaccine booster in the sample from 4 provinces in mainland China, namely Heilongjiang, Jiangsu, Henan, and Qinghai.</s><s xml:id="_dstsWaT">The vast majority of participants (6126/6659, 92%) indicated a willingness to receive the COVID-19 booster vaccine, with an additional 8% (533/6659) expressing vaccine hesitancy.</s><s xml:id="_hVEXN9A">The higher vaccination rate and lower vaccine hesitancy rate may be attributed to the following reasons: first, China has continued to strengthen postmarketing surveillance of vaccines, emphasizing their safety and efficacy while continuously tracking the incidence of vaccine-preventable diseases and public acceptance of vaccines <ref type="bibr" target="#b25">[26]</ref>.</s><s xml:id="_bYfp7bQ">Second, the Chinese government has increased the supply of COVID-19 vaccines and set up reasonably designated medical institutions to carry out booster vaccinations, which has improved the accessibility of vaccination services <ref type="bibr" target="#b30">[31]</ref>.</s><s xml:id="_2urZJDW">Finally, the government and communities have used instant communication media such as television, news, and radio to promote the idea that the overall benefits of COVID-19 vaccination outweigh the risks, and disseminated scientific knowledge about vaccination to reduce people's doubts.</s><s xml:id="_sVkfdFf">At the same time, community staff actively carried out door-to-door campaigns to mobilize residents actively participate in the booster vaccination.</s></p><p xml:id="_9m72w8S"><s xml:id="_8PWnAF9">Nevertheless, the hesitancy rate altered dynamically, increasing from 8% (533/6659) to 11% (736/6659) at the next regular COVID-19 booster vaccination.</s><s xml:id="_kjnAuZg">This may be related to the rapid mutation of the COVID-19 virus <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b31">32]</ref> and spot outbreaks in some cities such as Shanghai, Hainan, Zhengzhou, and so forth in mainland China <ref type="bibr">[33]</ref>.</s><s xml:id="_qJAGzpq">People are beginning to wonder about the necessity of the COVID-19 booster vaccination and whether it is effective and safe.</s><s xml:id="_3bS8gAv">This result suggests that repeated outbreaks or spot outbreaks are destroying confidence in the COVID-19 vaccine, which will not be conducive to the control of the epidemic.</s><s xml:id="_7hwC7Pd">Therefore, it would be relevant to explore the main influences on vaccine hesitancy and its dynamic fluctuations.</s></p><p xml:id="_R6Qnk3Y"><s xml:id="_MwTeP6A">Previous studies have indicated that participants with a lower education level expressed a higher level of COVID-19 vaccine hesitancy in a global survey of 17 countries <ref type="bibr" target="#b32">[34]</ref>, adults in Ontario with less than a bachelor degree were more likely to report unwillingness to COVID-19 vaccination <ref type="bibr" target="#b33">[35]</ref>, as well as Chinese adults with lower education level endorsed clear vaccine hesitancy response in primary COVID-19 vaccination <ref type="bibr" target="#b25">[26]</ref>.</s><s xml:id="_4atffBh">However, our findings suggest the opposite view.</s><s xml:id="_daE3FHV">Those participants with higher levels of education were more reluctant to participate in the regular COVID-19 booster vaccination, showing a clear vaccine hesitancy.</s><s xml:id="_BUGmXDj">Previous studies have demonstrated similar results <ref type="bibr" target="#b34">[36,</ref><ref type="bibr" target="#b35">37]</ref>.</s><s xml:id="_kqwNdev">Likewise, a similar trend was observed in the regular and the booster vaccination attitude conversion (ATH and HTH).</s><s xml:id="_f5RbHgZ">The reason for the contrary findings could be attributed to the fact that individuals with a higher level of education may have greater access to information regarding the COVID-19 outbreak and vaccine.</s><s xml:id="_89gpTDe">This may lead them to believe that the epidemic will come to an end soon and that they will no longer require a booster shot for COVID-19 <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s xml:id="_QHs4yeZ">Alternatively, the highly educated population may have more resources to combat the risk of the COVID-19 epidemic <ref type="bibr" target="#b36">[38,</ref><ref type="bibr" target="#b37">39]</ref>.</s></p><p xml:id="_HBaNcyC"><s xml:id="_E7rJ2Dw">It is worth noting that there was a significant association between experiencing chronic disease, history of previous vaccination allergies, and participants' hesitancy to receive booster vaccinations.</s><s xml:id="_kpKmAyY">This hesitancy was also found in the conversion of attitudes from booster vaccination to regular booster vaccination.</s><s xml:id="_qK75rm3">Participants with chronic diseases (hypertension, diabetes, etc) expressed clear hesitancy to receive booster vaccinations and were consistently hesitant to receive regular booster vaccinations.</s><s xml:id="_P2nM2Zd">The reason for this consequence may be that people with chronic disease were concerned about whether people with immunodeficiency and immunosuppression should be vaccinated <ref type="bibr" target="#b38">[40,</ref><ref type="bibr" target="#b39">41]</ref>.</s><s xml:id="_H4RxdVB">They are confused as to whether having a chronic disease can exacerbate adverse reactions to COVID-19 booster vaccination <ref type="bibr" target="#b40">[42,</ref><ref type="bibr" target="#b41">43]</ref>.</s><s xml:id="_FB28HTy">The same trend can be observed in participants with a history of vaccination allergy.</s><s xml:id="_SeKUEzj">Previous experiences with vaccination allergies have made people wary of the COVID-19 vaccine <ref type="bibr" target="#b42">[44]</ref>.</s><s xml:id="_pd4dZkt">They are unsure if they will develop allergic injuries after the COVID-19 booster vaccination <ref type="bibr" target="#b43">[45]</ref>, so hesitancy about the booster is inevitable.</s><s xml:id="_jk2WubG">Consequently, widespread education of people would be essential to reduce vaccine hesitancy.</s></p><p xml:id="_79vPQdp"><s xml:id="_Eaqghwk">In this study, we found that participants with higher levels of epidemic severity, barriers, and lower levels of susceptibility, benefits, and self-efficacy were more hesitant to receive a booster vaccination.</s><s xml:id="_TXGuy6F">The severity of the epidemic influenced people's choice, with higher levels of severity instead promoting vaccine hesitancy, which is inconsistent with previous findings <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b44">46]</ref>.</s><s xml:id="_P6JrrQH">This may be due to people being more aware of self-protection, taking more adequate self-protection measures, going out less, or participating in timely nucleic acid testing when the epidemic is severe <ref type="bibr" target="#b45">[47,</ref><ref type="bibr" target="#b46">48]</ref>.</s><s xml:id="_Fn6GcGR">Although most people have confidence in the vaccine, this attitude does not automatically translate into vaccine use, as there are a variety of other barriers to vaccination <ref type="bibr" target="#b47">[49,</ref><ref type="bibr" target="#b48">50]</ref>.</s><s xml:id="_qrzrPtt">While barriers to vaccination (eg, inconvenience and long queues) affect booster vaccination rates, a reasonable number of booster vaccination sites can facilitate vaccination <ref type="bibr" target="#b36">[38]</ref>, and the current high rate of COVID-19 vaccination in China can be attributed to a large number of vaccination sites.</s><s xml:id="_cyZSsfT">Therefore, in order to increase the booster vaccination rate, it is important to improve the accessibility of vaccination services.</s><s xml:id="_UxK8Mk3">Besides, effective measures can be taken simultaneously, including ensuring the supply of vaccines, increasing the number of vaccination staff, improving the vaccination experience, and providing appointment services to reduce the waiting time for vaccination <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b48">50,</ref><ref type="bibr" target="#b49">51]</ref>.</s><s xml:id="_PnvruPk">Consistent with the results of Włodarczyk and Ziętalewicz <ref type="bibr" target="#b50">[52]</ref>, higher self-efficacy and the benefits of COVID-19 vaccination influenced people to take part in vaccination, suggesting that we need to expand the perception that the benefits of vaccination outweigh the disadvantages and guide people positively to take part in vaccination with full self-efficacy.</s></p><p xml:id="_AdecNQg"><s xml:id="_JDxbukH">Mistrust of medical staff and vaccine developers is an important factor influencing hesitancy in receiving COVID-19 booster vaccination.</s><s xml:id="_6HF7cj8">This has been demonstrated in previous studies of vaccine hesitancy <ref type="bibr" target="#b51">[53]</ref><ref type="bibr" target="#b52">[54]</ref><ref type="bibr" target="#b53">[55]</ref>.</s><s xml:id="_QeTF3mC">Low levels of trust in medical staff and developers can lead to hesitancy in receiving COVID-19 booster vaccinations, even regular booster vaccinations.</s><s xml:id="_KFHqQ9t">Both experiences of adverse reactions to vaccinations and even the influence of counterfeit vaccines in society have led to suspicion of medical staff and developers <ref type="bibr" target="#b54">[56,</ref><ref type="bibr" target="#b55">57]</ref>, which directly influences the COVID-19 booster vaccination.</s><s xml:id="_qMXAaTG">Therefore, it is imperative to strengthen the regulation of vaccine development, production, transportation, and vaccination.</s><s xml:id="_B35ngbG">Strict adherence to XSL • FO RenderX industry guidelines and ethical standards will strongly ensure the standardization, safety, and efficacy of vaccines <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b56">58]</ref>.</s><s xml:id="_2JaWFxy">At the same time, it is necessary to strengthen the training of medical staff to enhance the communication between medical staff and residents, which aims to improve the quality of vaccination services.</s><s xml:id="_NNSDKT2">In addition, enhanced screening of patients with contraindications to COVID-19 vaccination is necessary <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b57">59]</ref>, and avoiding or delaying vaccination of contraindicated patients will effectively reduce the occurrence and adverse effects of allergic events.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jQYNajU">Strengths and Limitations</head><p xml:id="_Z8qnnpw"><s xml:id="_4cMGWjf">This is the first multicenter nationwide household-based survey to assess the hesitancy of COVID-19 booster vaccination, influencing factors, and its dynamic fluctuation trend with the help of a saturation sample, which is highly innovative and forward-looking.</s><s xml:id="_e44t3HT">Throughout the survey process, dedicated staff were assigned to follow-up the survey sites in each of the 4 centers, and strict quality control was carried out to ensure that the survey data were complete and authentic.</s><s xml:id="_2y6TNr7">However, there are still several limitations of this study.</s><s xml:id="_FrMhgfr">First, this study is a cross-sectional observational study, the causality association of vaccine hesitancy cannot be established, and it needs to be supported by data from the follow-up surveys.</s><s xml:id="_UaygHUV">Second, it may introduce reporting bias in the collecting data on COVID-19 booster vaccination.</s><s xml:id="_K7W7Nae">Finally, this survey was conducted on a household-based sample with a population of permanent residents, and the findings may not be applicable to the floating population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dXwvqKk">Conclusions</head><p xml:id="_8dPDmpV"><s xml:id="_N6PrpSk">The prevalence of COVID-19 vaccine booster hesitancy is not high in mainland China.</s><s xml:id="_WQMaX6e">However, there is a slight increment in hesitancy on regular booster vaccination.</s><s xml:id="_2nPm9Tp">To reduce vaccine hesitancy, targeted information guidance for people with higher education levels and chronic diseases would be fruitful.</s><s xml:id="_U9kPgdY">Furthermore, improving the accessibility of booster vaccination and enhancing people's trust in medical staff and vaccine developers would be highly effective in reducing vaccine hesitancy.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p xml:id="_zVUT7AA"><s xml:id="_xgujxWE">Figure 1.</s><s xml:id="_dEYkdqv">Flowchart of data processing and analysis.</s></p></div></figDesc><graphic coords="4,56.69,82.39,481.83,321.22" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p xml:id="_4rTJQKy"><s xml:id="_xzH5MdF">Figure 2. Influencing factors of vaccine hesitancy in both booster and regular booster vaccinations.</s></p></div></figDesc><graphic coords="8,56.69,82.30,481.92,578.31" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p xml:id="_k3xjvUY"><s xml:id="_3fqFDcz">Figure 3. COVID-19 vaccine hesitancy rates for different influencing factors in both booster and regular booster vaccination.</s></p></div></figDesc><graphic coords="9,56.69,190.38,481.83,311.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>.Figure 4 .Figure 5 .</head><label>45</label><figDesc><div><p xml:id="_FKQsm4Q"><s xml:id="_cKNcx7t">Figure 4. Relevant influences on acceptance to acceptance and acceptance to hesitancy for all participants.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_xhTRmFd"><s xml:id="_FtsPreS">The characteristics and COVID-19 vaccine booster hesitancy of all study participants in China (n=6659).</s></p></div></figDesc><table><row><cell>Covariates</cell><cell>Total, n (%)</cell><cell>P value a</cell><cell>Vaccine hesitancy in booster vaccination (95% CI) b</cell><cell>P value</cell><cell>Vaccine hesitancy in regular booster vaccination (95% CI)</cell><cell>P value</cell></row><row><cell>Total participants</cell><cell>6659 (100)</cell><cell></cell><cell>8.0 (7.4-8.7)</cell><cell></cell><cell>11.1 (10.3-11.8)</cell><cell></cell></row><row><cell>Age (years)</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>&lt;.001</cell></row><row><cell>18-29</cell><cell>872 (13.1)</cell><cell></cell><cell>7.8 (6.0-9.6)</cell><cell></cell><cell>11.0 (8.9-13.1)</cell><cell></cell></row><row><cell>30-39</cell><cell>1801 (27)</cell><cell></cell><cell>9.6 (8.2-10.9)</cell><cell></cell><cell>12.8 (11.3-14.5)</cell><cell></cell></row><row><cell>40-49</cell><cell>1277 (19.2)</cell><cell></cell><cell>6.2 (4.9-7.7)</cell><cell></cell><cell>9.9 (8.2-11.5)</cell><cell></cell></row><row><cell>50-59</cell><cell>1408 (21.1)</cell><cell></cell><cell>6.0 (4.7-7.2)</cell><cell></cell><cell>8.2 (6.8-9.7)</cell><cell></cell></row><row><cell>≥60</cell><cell>1301 (19.5)</cell><cell></cell><cell>10.0 (8.4-11.6)</cell><cell></cell><cell>12.9 (11.1-14.7)</cell><cell></cell></row><row><cell>Gender</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>.16</cell><cell></cell><cell>.02</cell></row><row><cell>Male</cell><cell>3119 (46.8)</cell><cell></cell><cell>7.5 (6.6-8.5)</cell><cell></cell><cell>10.1 (9.0-11.2)</cell><cell></cell></row><row><cell>Female</cell><cell>3540 (53.2)</cell><cell></cell><cell>8.5 (7.5-9.4)</cell><cell></cell><cell>11.9 (10.9-13.0)</cell><cell></cell></row><row><cell>Ethnic groups</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>.42</cell><cell></cell><cell>.27</cell></row><row><cell>Han</cell><cell>6472 (97.2)</cell><cell></cell><cell>8.1 (7.4-8.7)</cell><cell></cell><cell>11.1 (10.4-11.9)</cell><cell></cell></row><row><cell>Minority</cell><cell>187 (2.8)</cell><cell></cell><cell>6.4 (2.9-9.9)</cell><cell></cell><cell>8.6 (4.6-12.6)</cell><cell></cell></row><row><cell>Religion</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>.54</cell><cell></cell><cell>.88</cell></row><row><cell>Atheist</cell><cell>6362 (95.5)</cell><cell></cell><cell>8.1 (7.4-8.7)</cell><cell></cell><cell>11.1 (10.3-11.8)</cell><cell></cell></row><row><cell>Others</cell><cell>297 (4.5)</cell><cell></cell><cell>7.1 (4.2-10.0)</cell><cell></cell><cell>10.8 (7.3-14.3)</cell><cell></cell></row><row><cell>Marital status</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>.12</cell><cell></cell><cell>.43</cell></row><row><cell>Married</cell><cell>5829 (87.5)</cell><cell></cell><cell>8.2 (7.5-8.9)</cell><cell></cell><cell>11.2 (10.4-12.0)</cell><cell></cell></row><row><cell>Others</cell><cell>830 (12.5)</cell><cell></cell><cell>6.6 (4.9-8.3)</cell><cell></cell><cell>10.2 (8.2-12.3)</cell><cell></cell></row><row><cell>Educational status</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>&lt;.001</cell></row><row><cell>Below high school</cell><cell>2882 (43.3)</cell><cell></cell><cell>6.6 (5.7-7.5)</cell><cell></cell><cell>8.4 (7.4-9.4)</cell><cell></cell></row><row><cell>High school graduate</cell><cell>1661 (24.9)</cell><cell></cell><cell>8.1 (6.8-9.4)</cell><cell></cell><cell>11.9 (10.4-13.5)</cell><cell></cell></row><row><cell>University graduate</cell><cell>2116 (31.8)</cell><cell></cell><cell>9.8 (8.6-11.1)</cell><cell></cell><cell>14.0 (12.5-15.5)</cell><cell></cell></row><row><cell>Subjective social status in China</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>.01</cell><cell></cell><cell>.003</cell></row><row><cell>Level 1 c</cell><cell>1942 (29.2)</cell><cell></cell><cell>7.8 (6.6-9.0)</cell><cell></cell><cell>9.9 (8.6-11.4)</cell><cell></cell></row><row><cell>Level 2 c</cell><cell>2825 (42.4)</cell><cell></cell><cell>9.0 (7.9-10.0)</cell><cell></cell><cell>12.4 (11.2-13.6)</cell><cell></cell></row><row><cell>Level 3 c</cell><cell>796 (12.0)</cell><cell></cell><cell>7.9 (6.0-9.8)</cell><cell></cell><cell>11.9 (9.7-14.2)</cell><cell></cell></row><row><cell>Level 4 c</cell><cell>1096 (16.5)</cell><cell></cell><cell>5.8 (4.5-7.2)</cell><cell></cell><cell>8.9 (7.2-10.5)</cell><cell></cell></row><row><cell cols="2">Subjective social status in community</cell><cell>&lt;.001</cell><cell></cell><cell>.01</cell><cell></cell><cell>&lt;.001</cell></row><row><cell>Level 1 c</cell><cell>1734 (26.0)</cell><cell></cell><cell>7.5 (6.3-8.8)</cell><cell></cell><cell>9.3 (7.9-10.7)</cell><cell></cell></row><row><cell>Level 2 c</cell><cell>2896 (43.5)</cell><cell></cell><cell>9.2 (8.1-10.2)</cell><cell></cell><cell>12.7 (11.5-13.9)</cell><cell></cell></row><row><cell>Level 3 c</cell><cell>858 (12.9)</cell><cell></cell><cell>7.6 (5.8-9.4)</cell><cell></cell><cell>11.9 (9.7-14.2)</cell><cell></cell></row><row><cell>Level 4 c</cell><cell>1171 (17.6)</cell><cell></cell><cell>6.2 (4.9-7.6)</cell><cell></cell><cell>9.0 (7.3-10.6)</cell><cell></cell></row><row><cell cols="2">Self-report health condition (EQ-5D) d</cell><cell>0.01</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>&lt;.001</cell></row><row><cell>Level 1 c</cell><cell>1709 (25.7)</cell><cell></cell><cell>13.0 (11.4-14.7)</cell><cell></cell><cell>16.3 (14.5-18.1)</cell><cell></cell></row><row><cell>Level 2 c</cell><cell>1627 (24.4)</cell><cell></cell><cell>7.9 (6.6-9.3)</cell><cell></cell><cell>11.0 (9.5-12.6)</cell><cell></cell></row><row><cell>Level 3 c</cell><cell>1746 (26.2)</cell><cell></cell><cell>5.7 (4.6-6.9)</cell><cell></cell><cell>9.5 (8.1-10.9)</cell><cell></cell></row><row><cell>Level 4 c</cell><cell>1577 (23.7)</cell><cell></cell><cell>5.3 (4.2-6.4)</cell><cell></cell><cell>7.2 (6.0-8.5)</cell><cell></cell></row><row><cell>Chronic disease</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>&lt;.001</cell></row><row><cell>XSL • FO</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>RenderX</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_Rwtb3p9"><s xml:id="_zM4eUQS">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 3 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_4S5KzAc">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_x77cjNN"><s xml:id="_qQkg53j">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 4 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_wSK8MQr">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p xml:id="_RkptMy5"><s xml:id="_C4GZEA2">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_3"><p xml:id="_cqsqdhT"><s xml:id="_FNRaU6m">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 6 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_7SvsCkE">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_4"><p xml:id="_B5XKpzP"><s xml:id="_BtYncNM">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 7 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_bnsFNA7">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_5"><p xml:id="_TuEkhNF"><s xml:id="_27FGuwP">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 8 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_HxmDbXu">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_6"><p xml:id="_vxxYx8P"><s xml:id="_vWGtZTq">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 9 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_uUpjW7J">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_7"><p xml:id="_F2c7pNQ"><s xml:id="_CZjYKdS">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 11 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_m4eQ2Jp">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_8"><p xml:id="_7YUtQaz"><s xml:id="_5uMwRzN">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 12 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_R8QKhx6">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_9"><p xml:id="_78vgAVa"><s xml:id="_4SPZJA6">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 13 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_vXPYax9">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_10"><p xml:id="_EBXdFHu"><s xml:id="_YErHVTX">JMIR Public Health Surveill 2023 | vol. 9 | e44822 | p. 17 https://publichealth.jmir.org/2023/1/e44822</s><s xml:id="_nbAjJqm">(page number not for citation purposes)</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_kNcYxvs">Acknowledgments</head><p xml:id="_2nx9zEX"><s xml:id="_Z6rVp34">This work was funded by the <rs type="funder">National Social Science Fund of China</rs> (<rs type="grantNumber">21BGL222</rs>); the <rs type="funder">Henan Provincial University Philosophy and Social Science Innovation Talent Support Plan</rs> (<rs type="grantNumber">2023-CXRC-06</rs>); and the <rs type="funder">2023 Graduate Independent Innovation Project of Zhengzhou University</rs> (<rs type="grantNumber">20230440</rs>).</s><s xml:id="_sh52Z3y">The authors would like to thank all participants for their involvement.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_qHecYkB">
					<idno type="grant-number">21BGL222</idno>
				</org>
				<org type="funding" xml:id="_aBqqSPx">
					<idno type="grant-number">2023-CXRC-06</idno>
				</org>
				<org type="funding" xml:id="_EP5cmwn">
					<idno type="grant-number">20230440</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WQRhGth">Data Availability</head><p xml:id="_pa2UaQ4"><s xml:id="_A5gFPN2">The data sets generated and analyzed during this study are available from the corresponding author on reasonable request.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cAxXspX">Authors' Contributions</head><p xml:id="_bKXxfuM"><s xml:id="_wGZFkyC">BY, YM, and JW contributed to the conceptualization.</s><s xml:id="_3MXWe5c">XZ, BY, QL, and MM contributed to the methodology.</s><s xml:id="_yMDs5HV">BY and JW contributed to the formal analysis.</s><s xml:id="_MjkCS3s">JW, YM, XZ, QL, and MM contributed to the investigation.</s><s xml:id="_Vd7Jnn5">YM, MM, XG, and SJ contributed to the data curation.</s><s xml:id="_vVw2hBC">MM and XG contributed to the software.</s><s xml:id="_Gqh3Bkx">BY, MW, and JG contributed to the funding acquisition.</s><s xml:id="_2V2bk3N">JW and YM contributed to the project administration.</s><s xml:id="_qBqycFH">MM contributed to writing-original draft.</s><s xml:id="_45zajp8">JW, CST, and BY contributed to writing-review and editing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bjQcbNK">Conflicts of Interest</head><p xml:id="_uUaSPQ2"><s xml:id="_VMg3fv8">None declared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_b4AUJ4T">Multimedia Appendix 1</head><p xml:id="_gKzNBUx"><s xml:id="_6aeGqRr">Original questionnaire: data collection and explanatory variables.</s></p><p xml:id="_NpVAgge"><s xml:id="_S6Gq4wx">[DOCX File , 64 KB-Multimedia Appendix 1]</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FBTXENz">Multimedia Appendix 2</head><p xml:id="_X3UK4vf"><s xml:id="_4PMgdHu">Analysis of variance between the participants (n=6659) included in the analysis and the total sample (N=8002).</s></p><p xml:id="_j4b2AUD"><s xml:id="_GvAUZBb">[DOCX File , 17 KB-Multimedia Appendix 2]</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YrMN2Eh">Multimedia Appendix 3</head><p xml:id="_g7qZzzT"><s xml:id="_snetQmh">The effect factors of vaccine hesitancy in both the booster and regular booster vaccination (n=6659).</s></p><p xml:id="_4j2M2gp"><s xml:id="_Uz4gcmY">[DOCX File , 46 KB-Multimedia <ref type="bibr">Appendix 3]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NujZfyw">Multimedia Appendix 4</head><p xml:id="_jbGBGcP"><s xml:id="_qykSxnp">Associations between COVID-19 booster vaccination acceptance, hesitancy transitions, and characteristics of all participants (n=6659).</s></p><p xml:id="_5aX3XQx"><s xml:id="_WJu4f7U">[DOCX File , 47 KB-Multimedia Appendix 4]</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2SX5XaM">Multimedia Appendix 5</head><p xml:id="_S8B8baR"><s xml:id="_BCkgSDz">The sensitivity analyses of factors influence booster and regular booster vaccination (n=6239 This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ref type="url" target="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ref>),</s><s xml:id="_7Aehnw5">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited.</s><s xml:id="_hMyzMCg">The complete bibliographic information, a link to the original publication on <ref type="url" target="https://publichealth.jmir.org">https://publichealth.jmir.org</ref>,</s><s xml:id="_Q2sEFhT">as well as this copyright and license information must be included.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_XwndqsH">Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Muecksch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schaefer-Babajew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Finkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Viant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gaebler</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41586-021-03696-9</idno>
		<idno>Medline: 34126625</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WRKG2YC">Nature</title>
		<imprint>
			<biblScope unit="volume">595</biblScope>
			<biblScope unit="issue">7867</biblScope>
			<biblScope unit="page" from="426" to="431" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021;595(7867):426-431 [FREE Full text] [doi: 10.1038/s41586-021-03696-9] [Medline: 34126625]</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_xVVbcHZ">Herd immunity for COVID-19</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Burki</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2213-2600(20)30555-5</idno>
		<idno>Medline: 33245861</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QQsJcKw">Lancet Respir Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="135" to="136" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Burki TK. Herd immunity for COVID-19. Lancet Respir Med 2021;9(2):135-136 [FREE Full text] [doi: 10.1016/S2213-2600(20)30555-5] [Medline: 33245861]</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_UkrE6Fg">COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries</title>
		<author>
			<persName><forename type="first">Jss</forename><surname>Arce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Warren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Meriggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scacco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mcmurry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Voors</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41591-021-01454-y</idno>
		<idno>Medline: 34272499</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ufVcUd2">Nat Med</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1385" to="1394" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Arce JSS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries. Nat Med 2021;27(8):1385-1394 [FREE Full text] [doi: 10.1038/s41591-021-01454-y] [Medline: 34272499]</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_HPRnEva">Influenza and other Viruses in the AcutelY ill (IVY) Network. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Rhoads</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Surie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gaglani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Ginde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mcneal</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj-2022-072065</idno>
		<idno>Medline: 36220174</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8GmQdq9">BMJ</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page">72065</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, Influenza and other Viruses in the AcutelY ill (IVY) Network. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. BMJ 2022;379:e072065 [FREE Full text] [doi: 10.1136/bmj-2022-072065] [Medline: 36220174]</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_pd8YygF">Mobile health services for COVID-19: counseling, testing, and vaccination for medically underserved populations</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Mohareb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Valdes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jollife</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Regis</surname></persName>
		</author>
		<idno type="DOI">10.2105/ajph.2022.307021</idno>
		<idno>Medline: 36223583</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NMwucVW">Am J Public Health</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1556" to="1559" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Gupta PS, Mohareb AM, Valdes C, Price C, Jollife M, Regis C, et al. Mobile health services for COVID-19: counseling, testing, and vaccination for medically underserved populations. Am J Public Health 2022;112(11):1556-1559 [FREE Full text] [doi: 10.2105/AJPH.2022.307021] [Medline: 36223583]</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<author>
			<orgName type="collaboration">WHO</orgName>
		</author>
		<idno type="DOI">10.1093/ww/9780199540884.013.u7971</idno>
		<ptr target="https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-13th-meeting-of-the-ihr-emergency-committee-on-covid-19-pandemic---13-october-2022" />
		<title level="m" xml:id="_PW9rm8P">General&apos;s opening remarks at the 13th meeting of the IHR Emergency Committee on COVID-19 pandemic</title>
		<imprint>
			<date type="published" when="2023-06-22">2023-06-22</date>
		</imprint>
		<respStmt>
			<orgName>WHO</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">WHO Director-General&apos;s opening remarks at the 13th meeting of the IHR Emergency Committee on COVID-19 pandemic. WHO. URL: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-13th- meeting-of-the-ihr-emergency-committee-on-covid-19-pandemic---13-october-2022 [accessed 2023-06-22]</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_2EHPeQE">Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leonard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Hoggatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Boscardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Lum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Moss</forename><forename type="middle">-</forename><surname>Vazquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.1001/jama.2022.17985</idno>
		<idno>Medline: 36156706</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7zuRxFV">JAMA</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1427" to="1437" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Kelly JD, Leonard S, Hoggatt KJ, Boscardin WJ, Lum EN, Moss-Vazquez TA, et al. Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines. JAMA 2022;328(14):1427-1437 [FREE Full text] [doi: 10.1001/jama.2022.17985] [Medline: 36156706]</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_kXmjbpj">Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mrak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sieghart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Simader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tobudic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Radner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mandl</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-022-33036-y</idno>
		<idno>Medline: 36097029</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_B2qNtTe">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">5362</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun 2022;13(1):5362 [FREE Full text] [doi: 10.1038/s41467-022-33036-y] [Medline: 36097029]</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_mbjxKjs">Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gilboa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Regev-Yochay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mandelboim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Indenbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Asraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fluss</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamanetworkopen.2022.31778</idno>
		<idno>Medline: 36107426</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Tk4tmWB">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">2231778</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Gilboa M, Regev-Yochay G, Mandelboim M, Indenbaum V, Asraf K, Fluss R, et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection. JAMA Netw Open 2022;5(9):e2231778 [FREE Full text] [doi: 10.1001/jamanetworkopen.2022.31778] [Medline: 36107426]</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_GU9h2Kv">Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the omicron (B.1.1.529) variant era</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Ioannou</surname></persName>
			<affiliation>
				<orgName type="collaboration">Observational Research Collaboratory</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Asb</forename><surname>Bohnert</surname></persName>
			<affiliation>
				<orgName type="collaboration">Observational Research Collaboratory</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Hare</surname></persName>
			<affiliation>
				<orgName type="collaboration">Observational Research Collaboratory</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Boyko</surname></persName>
			<affiliation>
				<orgName type="collaboration">Observational Research Collaboratory</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Maciejewski</surname></persName>
			<affiliation>
				<orgName type="collaboration">Observational Research Collaboratory</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
			<affiliation>
				<orgName type="collaboration">Observational Research Collaboratory</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename></persName>
			<affiliation>
				<orgName type="collaboration">Observational Research Collaboratory</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Covid-19 ;</forename><surname>Corc</surname></persName>
			<affiliation>
				<orgName type="collaboration">Observational Research Collaboratory</orgName>
			</affiliation>
		</author>
		<idno type="DOI">10.7326/m22-1856</idno>
		<idno>Medline: 36215715</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HgWG8MJ">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1693" to="1706" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Ioannou GN, Bohnert ASB, O&apos;Hare AM, Boyko EJ, Maciejewski ML, Smith VA, COVID-19 Observational Research Collaboratory (CORC). Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the omicron (B.1.1.529) variant era. Ann Intern Med 2022;175(12):1693-1706 [FREE Full text] [doi: 10.7326/M22-1856] [Medline: 36215715]</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_QSqWVrC">The elusive goal of COVID-19 vaccine immunity</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Abu-Raddad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chemaitelly</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2213-2600(22)00394-0</idno>
		<idno>Medline: 36216010</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Pe5WuUy">Lancet Respir Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="115" to="117" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Abu-Raddad LJ, Chemaitelly H. The elusive goal of COVID-19 vaccine immunity. Lancet Respir Med 2023;11(2):115-117 [FREE Full text] [doi: 10.1016/S2213-2600(22)00394-0] [Medline: 36216010]</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_ZDc9uvN">COVID-19 vaccination acceptance among Chinese population and its implications for the pandemic: a national cross-sectional study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Tarimo</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpubh.2022.796467</idno>
		<idno>Medline: 35211440</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4kruSUv">Front Public Health</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">796467</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Wu J, Ma M, Miao Y, Ye B, Li Q, Tarimo CS, et al. COVID-19 vaccination acceptance among Chinese population and its implications for the pandemic: a national cross-sectional study. Front Public Health 2022;10:796467 [FREE Full text] [doi: 10.3389/fpubh.2022.796467] [Medline: 35211440]</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<idno type="DOI">10.31219/osf.io/fn46p</idno>
		<ptr target="https://www.who.int/zh/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection" />
		<title level="m" xml:id="_u5MuzNT">Vaccine efficacy, effectiveness and protection</title>
		<imprint>
			<publisher>WHO</publisher>
			<date type="published" when="2021-07-14">2021. 2021-07-14</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vaccine efficacy, effectiveness and protection. WHO. 2021. URL: https://www.who.int/zh/news-room/feature-stories/ detail/vaccine-efficacy-effectiveness-and-protection [accessed 2021-07-14]</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_yFDtE7F">How to tackle inequitable access, vaccine hesitancy, and other barriers to achieve high vaccine uptake</title>
		<author>
			<persName><forename type="first">N</forename><surname>Berdzuli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Datta</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.o1094</idno>
		<idno>Medline: 35487528</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QKk2nJV">BMJ</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page">1094</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Berdzuli N, Datta SS. How to tackle inequitable access, vaccine hesitancy, and other barriers to achieve high vaccine uptake. BMJ 2022;377:o1094 [FREE Full text] [doi: 10.1136/bmj.o1094] [Medline: 35487528]</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_yPHMTGS">Theater for vaccine hesitancy-setting the stage for difficult conversations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Russ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Russell</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2022.14864</idno>
		<idno>Medline: 36053542</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_um3JAjr">JAMA</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1018" to="1019" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Cullen JP, Russ S, Russell HA. Theater for vaccine hesitancy-setting the stage for difficult conversations. JAMA 2022;328(11):1018-1019 [FREE Full text] [doi: 10.1001/jama.2022.14864] [Medline: 36053542]</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_H9U72cs">A systematic literature review to clarify the concept of vaccine hesitancy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Bussink-Voorend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jla</forename><surname>Hautvast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vandeberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mejl</forename><surname>Hulscher</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41562-022-01431-6</idno>
		<idno>Medline: 35995837</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mJqyMgD">Nat Hum Behav</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1634" to="1648" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Bussink-Voorend D, Hautvast JLA, Vandeberg L, Visser O, Hulscher MEJL. A systematic literature review to clarify the concept of vaccine hesitancy. Nat Hum Behav 2022;6(12):1634-1648 [FREE Full text] [doi: 10.1038/s41562-022-01431-6] [Medline: 35995837]</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_HAyXru8">Should measles vaccination be compulsory?</title>
		<author>
			<persName><forename type="first">E</forename><surname>Draeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Bedford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dac</forename><surname>Elliman</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.l2359</idno>
		<idno>Medline: 31167804</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VHd2Bps">BMJ</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page">2359</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Draeger E, Bedford HE, Elliman DAC. Should measles vaccination be compulsory? BMJ 2019;365:l2359 [doi: 10.1136/bmj.l2359] [Medline: 31167804]</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_BRYGWwN">Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant</title>
		<author>
			<persName><forename type="first">T</forename><surname>Trakarnvanich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ngamvichchukorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Phumisantiphong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pholtawornkulchai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Phochanasomboon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Manomaipiboon</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2022.09.067</idno>
		<idno>Medline: 36202639</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_S6eXJ8R">Vaccine</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">45</biblScope>
			<biblScope unit="page" from="6499" to="6511" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Trakarnvanich T, Ngamvichchukorn T, Phumisantiphong U, Pholtawornkulchai K, Phochanasomboon K, Manomaipiboon A. Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant. Vaccine 2022;40(45):6499-6511 [FREE Full text] [doi: 10.1016/j.vaccine.2022.09.067] [Medline: 36202639]</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_TFbZfYx">COVID-19 vaccine-related attitudes and beliefs in Canada: national cross-sectional survey and cluster analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Benham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Atabati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Oxoby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mourali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shaffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sheikh</surname></persName>
		</author>
		<idno type="DOI">10.2196/30424</idno>
		<idno>Medline: 34779784</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fwTdSdr">JMIR Public Health Surveill</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">30424</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Benham JL, Atabati O, Oxoby RJ, Mourali M, Shaffer B, Sheikh H, et al. COVID-19 vaccine-related attitudes and beliefs in Canada: national cross-sectional survey and cluster analysis. JMIR Public Health Surveill 2021;7(12):e30424 [FREE Full text] [doi: 10.2196/30424] [Medline: 34779784]</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_nRY4wpe">Nudging toward vaccination: a systematic review</title>
		<author>
			<persName><forename type="first">Mdc</forename><surname>Reñosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Landicho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wachinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Dalglish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bärnighausen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bärnighausen</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjgh-2021-006237</idno>
		<idno>Medline: 34593513</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fKttqCN">BMJ Glob Health</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">6237</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Reñosa MDC, Landicho J, Wachinger J, Dalglish SL, Bärnighausen K, Bärnighausen T, et al. Nudging toward vaccination: a systematic review. BMJ Glob Health 2021;6(9):e006237 [FREE Full text] [doi: 10.1136/bmjgh-2021-006237] [Medline: 34593513]</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_RKBSKXU">COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout</title>
		<author>
			<persName><forename type="first">A</forename><surname>Byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Filipp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ryan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2022.09.090</idno>
		<idno>Medline: 36220714</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bm5AXJV">Vaccine</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">46</biblScope>
			<biblScope unit="page" from="6680" to="6687" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Byrne A, Thompson LA, Filipp SL, Ryan K. COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout. Vaccine 2022;40(46):6680-6687 [FREE Full text] [doi: 10.1016/j.vaccine.2022.09.090] [Medline: 36220714]</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_w8QCEse">Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loomba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>De Figueiredo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Piatek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>De Graaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Larson</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41562-021-01056-1</idno>
		<idno>Medline: 33547453</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JRXgK2e">Nat Hum Behav</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="337" to="348" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nat Hum Behav 2021;5(3):337-348 [FREE Full text] [doi: 10.1038/s41562-021-01056-1] [Medline: 33547453]</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_6mZxKKk">COVID-19 vaccine hesitancy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Dubé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Macdonald</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41581-022-00571-2</idno>
		<idno>Medline: 35414006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PFxWdUU">Nat Rev Nephrol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="409" to="410" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Dubé E, MacDonald NE. COVID-19 vaccine hesitancy. Nat Rev Nephrol 2022;18(7):409-410 [FREE Full text] [doi: 10.1038/s41581-022-00571-2] [Medline: 35414006]</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_8kXccPx">COVID-19 vaccination coverage among people experiencing homelessness in a highly vaccinated Midwest County-Dane County, Wisconsin</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Neuschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mcbride</surname></persName>
		</author>
		<idno type="DOI">10.1093/infdis/jiac303</idno>
		<idno>Medline: 36208167</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZEDg8rs">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="issue">Suppl 3</biblScope>
			<biblScope unit="page" from="335" to="S339" />
			<date type="published" when="2021">2021. 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Gibson C, Schumann C, Neuschel K, McBride JA. COVID-19 vaccination coverage among people experiencing homelessness in a highly vaccinated Midwest County-Dane County, Wisconsin, 2021. J Infect Dis 2022;226(Suppl 3):S335-S339 [FREE Full text] [doi: 10.1093/infdis/jiac303] [Medline: 36208167]</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_dhnW5cJ">Evaluation of the safety profile of COVID-19 vaccines: a rapid review</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Z</forename><surname>Dudley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhuang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12916-021-02059-5</idno>
		<idno>Medline: 34315454</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MAWRZbV">BMC Med</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">173</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med 2021;19(1):173 [FREE Full text] [doi: 10.1186/s12916-021-02059-5] [Medline: 34315454]</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_Fw2zFQa">COVID-19 vaccine hesitancy among Chinese population: a large-scale national study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Tarimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2021.781161</idno>
		<idno>Medline: 34912346</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cyk8EXM">Front Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">781161</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Wu J, Li Q, Tarimo CS, Wang M, Gu J, Wei W, et al. COVID-19 vaccine hesitancy among Chinese population: a large-scale national study. Front Immunol 2021;12:781161 [FREE Full text] [doi: 10.3389/fimmu.2021.781161] [Medline: 34912346]</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_zJZuxn9">Unfolding the determinants of COVID-19 vaccine acceptance in China</title>
		<author>
			<persName><forename type="first">F</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ji</forename><forename type="middle">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename></persName>
		</author>
		<idno type="DOI">10.2196/26089</idno>
		<idno>Medline: 33400682</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TctqyTx">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">26089</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Yin F, Wu Z, Xia X, Ji M, Wang Y, Hu Z. Unfolding the determinants of COVID-19 vaccine acceptance in China. J Med Internet Res 2021;23(1):e26089 [FREE Full text] [doi: 10.2196/26089] [Medline: 33400682]</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_n7gh8ze">Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dennis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Cuthbertson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wootton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Crooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gabbay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Eichert</surname></persName>
		</author>
		<idno type="DOI">10.1177/01410768231154703</idno>
		<idno>Medline: 36787802</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Fa55BMJ">J R Soc Med</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="97" to="112" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Dennis A, Cuthbertson DJ, Wootton D, Crooks M, Gabbay M, Eichert N, et al. Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study. J R Soc Med 2023;116(3):97-112 [FREE Full text] [doi: 10.1177/01410768231154703] [Medline: 36787802]</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_8UnhFB5">Neuromyelitis Optica Study Group (NEMOS). Effects of the COVID-19 pandemic on patients with NMO spectrum disorders and MOG-antibody-associated diseases: COPANMO(G)-study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Hümmert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bütow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tkachenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ayzenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pakeerathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hellwig</surname></persName>
		</author>
		<idno type="DOI">10.1212/NXI.0000000000200082</idno>
		<idno>Medline: 36693760</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wm5PMx6">Neurol Neuroimmunol Neuroinflamm</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">200082</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Neuromyelitis Optica Study Group (NEMOS). Effects of the COVID-19 pandemic on patients with NMO spectrum disorders and MOG-antibody-associated diseases: COPANMO(G)-study. Neurol Neuroimmunol Neuroinflamm 2023;10(2):e200082 [FREE Full text] [doi: 10.1212/NXI.0000000000200082] [Medline: 36693760]</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_yJVgp8S">Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Bahmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Borzikowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lieb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Horn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Krist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fricke</surname></persName>
		</author>
		<author>
			<persName><surname>Napkon</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eclinm.2022.101549</idno>
		<idno>Medline: 35875815</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3fvCTdE">EClinicalMedicine</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page">101549</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Bahmer T, Borzikowsky C, Lieb W, Horn A, Krist L, Fricke J, NAPKON study group. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study. EClinicalMedicine 2022;51:101549 [FREE Full text] [doi: 10.1016/j.eclinm.2022.101549] [Medline: 35875815]</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_zv6Epyd">Decreased influenza vaccination coverage among Chinese healthcare workers during the COVID-19 pandemic</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1186/s40249-022-01029-0</idno>
		<idno>Medline: 36209258</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yrrnet9">Infect Dis Poverty</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">105</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Ma L, Han X, Ma Y, Yang Y, Xu Y, Liu D, et al. Decreased influenza vaccination coverage among Chinese healthcare workers during the COVID-19 pandemic. Infect Dis Poverty 2022;11(1):105 [FREE Full text] [doi: 10.1186/s40249-022-01029-0] [Medline: 36209258]</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_pDgUsuu">Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Mcmenamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nealon</forename><forename type="middle">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ehy</forename></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(22)00345-0</idno>
		<idno>Medline: 35850128</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xJDKvtN">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1435" to="1443" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis 2022;22(10):1435-1443 [FREE Full text] [doi: 10.1016/S1473-3099(22)00345-0] [Medline: 35850128]</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_zcNtm69">COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Alias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Danaee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lachyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Z</forename><surname>Cai</surname></persName>
		</author>
		<idno type="DOI">10.1186/s40249-021-00900-w</idno>
		<idno>Medline: 34620243</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nYDvyBf">Infect Dis Poverty</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">122</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Wong LP, Alias H, Danaee M, Ahmed J, Lachyan A, Cai CZ, et al. COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries. Infect Dis Poverty 2021;10(1):122 [FREE Full text] [doi: 10.1186/s40249-021-00900-w] [Medline: 34620243]</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_vuKJU4Y">COVID-19 vaccine perceptions and differences by sex, age, and education in 1,367 community adults in Ontario</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Syan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Gohari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Levitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Belisario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dejesus</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpubh.2021.719665</idno>
		<idno>Medline: 34631647</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cE68FdX">Front Public Health</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">719665</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Syan SK, Gohari MR, Levitt EE, Belisario K, Gillard J, DeJesus J, et al. COVID-19 vaccine perceptions and differences by sex, age, and education in 1,367 community adults in Ontario. Front Public Health 2021;9:719665 [FREE Full text] [doi: 10.3389/fpubh.2021.719665] [Medline: 34631647]</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_ZxtvEqA">Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Lazarus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wyka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Picchio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Ratzan</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-022-31441-x</idno>
		<idno>Medline: 35778396</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EZBjtz9">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">3801</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Lazarus JV, Wyka K, White TM, Picchio CA, Rabin K, Ratzan SC, et al. Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nat Commun 2022;13(1):3801 [FREE Full text] [doi: 10.1038/s41467-022-31441-x] [Medline: 35778396]</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_m4UyBtd">Willingness to receive COVID-19 vaccination among people living with HIV and AIDS in China: nationwide cross-sectional online survey</title>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.2196/31125</idno>
		<idno>Medline: 34543223</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FAGpRyc">JMIR Public Health Surveill</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">31125</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Huang X, Yu M, Fu G, Lan G, Li L, Yang J, et al. Willingness to receive COVID-19 vaccination among people living with HIV and AIDS in China: nationwide cross-sectional online survey. JMIR Public Health Surveill 2021;7(10):e31125 [FREE Full text] [doi: 10.2196/31125] [Medline: 34543223]</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_Kf45Gtv">Vaccine hesitancy: the next challenge in the fight against COVID-19</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Dror</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Eisenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Taiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Morozov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mizrachi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zigron</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10654-020-00671-y</idno>
		<idno>Medline: 32785815</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3DGdXwH">Eur J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="775" to="779" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol 2020;35(8):775-779 [FREE Full text] [doi: 10.1007/s10654-020-00671-y] [Medline: 32785815]</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_Rkjhu9m">COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: cross-sectional, internet-based survey</title>
		<author>
			<persName><forename type="first">R</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hervey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Deighton</surname></persName>
		</author>
		<idno type="DOI">10.2196/29872</idno>
		<idno>Medline: 34709184</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9239jFN">JMIR Public Health Surveill</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">e29872</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Tsai R, Hervey J, Hoffman K, Wood J, Johnson J, Deighton D, et al. COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: cross-sectional, internet-based survey. JMIR Public Health Surveill 2022;8(1):e29872 [FREE Full text] [doi: 10.2196/29872] [Medline: 34709184]</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_Md6H46z">Diabetes and COVID-19: the past, the present, and the future</title>
		<author>
			<persName><forename type="first">R</forename><surname>Pranata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Henrina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Raffaello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lawrensia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.metabol.2021.154814</idno>
		<idno>Medline: 34119537</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6M2ufUG">Metabolism</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page">154814</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Pranata R, Henrina J, Raffaello WM, Lawrensia S, Huang I. Diabetes and COVID-19: the past, the present, and the future. Metabolism 2021;121:154814 [FREE Full text] [doi: 10.1016/j.metabol.2021.154814] [Medline: 34119537]</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_KTN7frw">Hemophagocytic lymphohistiocytosis after COVID-19 vaccination</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13045-021-01100-7</idno>
		<idno>Medline: 34088334</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aAnws5x">J Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">87</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Tang LV, Hu Y. Hemophagocytic lymphohistiocytosis after COVID-19 vaccination. J Hematol Oncol 2021;14(1):87 [FREE Full text] [doi: 10.1186/s13045-021-01100-7] [Medline: 34088334]</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_AN45psZ">Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine</title>
		<author>
			<persName><forename type="first">M</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Balena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tuccinardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Risi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Masi</surname></persName>
		</author>
		<idno type="DOI">10.1002/dmrr.3465</idno>
		<idno>Medline: 33955644</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CDvrhMY">Diabetes Metab Res Rev</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">3465</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev 2022;38(1):e3465 [FREE Full text] [doi: 10.1002/dmrr.3465] [Medline: 33955644]</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_FjZhYmz">Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Schrezenmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bergfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hillus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lippert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tober-Lau</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2021.690698</idno>
		<idno>Medline: 34276681</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eWyArzh">Front Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">690698</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Schrezenmeier E, Bergfeld L, Hillus D, Lippert JD, Weber U, Tober-Lau P, et al. Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis. Front Immunol 2021;12:690698 [FREE Full text] [doi: 10.3389/fimmu.2021.690698] [Medline: 34276681]</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_UGPUcqA">Allergy to COVID-19 vaccines: a current update</title>
		<author>
			<persName><forename type="first">B</forename><surname>Cabanillas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Novak</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.alit.2021.04.003</idno>
		<idno>Medline: 33962863</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dsuUgeq">Allergol Int</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="313" to="318" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Cabanillas B, Novak N. Allergy to COVID-19 vaccines: a current update. Allergol Int 2021;70(3):313-318 [FREE Full text] [doi: 10.1016/j.alit.2021.04.003] [Medline: 33962863]</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_qhA7wa4">Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the omicron variant in a large, population-based, Norwegian cohort</title>
		<author>
			<persName><forename type="first">I</forename><surname>Laake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Skodvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Blix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">H</forename><surname>Caspersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Gjessing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Juvet</surname></persName>
		</author>
		<idno type="DOI">10.1093/infdis/jiac419</idno>
		<idno>Medline: 36259543</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_T5XbrVu">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1924" to="1933" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Laake I, Skodvin SN, Blix K, Caspersen IH, Gjessing HK, Juvet LK, et al. Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the omicron variant in a large, population-based, Norwegian cohort. J Infect Dis 2022;226(11):1924-1933 [FREE Full text] [doi: 10.1093/infdis/jiac419] [Medline: 36259543]</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_6hBeXZZ">Prayer frequency and COVID-19 vaccine hesitancy among older adults in Europe</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Wester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Scheel-Hincke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bovil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Andersen-Ranberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Ahrenfeldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Hvidt</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2022.09.044</idno>
		<idno>Medline: 36182618</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DRNNpFX">Vaccine</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">44</biblScope>
			<biblScope unit="page" from="6383" to="6390" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Wester CT, Scheel-Hincke LL, Bovil T, Andersen-Ranberg K, Ahrenfeldt LJ, Hvidt NC. Prayer frequency and COVID-19 vaccine hesitancy among older adults in Europe. Vaccine 2022;40(44):6383-6390 [FREE Full text] [doi: 10.1016/j.vaccine.2022.09.044] [Medline: 36182618]</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_n4KaNk8">Community-level characteristics of COVID-19 vaccine hesitancy in England: a nationwide cross-sectional study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Bucyibaruta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Blangiardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Konstantinoudis</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10654-022-00905-1</idno>
		<idno>Medline: 36121531</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yx4zd6C">Eur J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1071" to="1081" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Bucyibaruta G, Blangiardo M, Konstantinoudis G. Community-level characteristics of COVID-19 vaccine hesitancy in England: a nationwide cross-sectional study. Eur J Epidemiol 2022;37(10):1071-1081 [FREE Full text] [doi: 10.1007/s10654-022-00905-1] [Medline: 36121531]</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_rfV6rEq">Investigating how historical legacies of militarized violence can motivate COVID-19 vaccine hesitancy: evidence from global dyadic survey</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Howell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Heinrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Motta</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.socscimed.2022.115346</idno>
		<idno>Medline: 36108562</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4frYdKT">Soc Sci Med</title>
		<imprint>
			<biblScope unit="volume">311</biblScope>
			<biblScope unit="page">115346</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Kobayashi Y, Howell C, Heinrich T, Motta M. Investigating how historical legacies of militarized violence can motivate COVID-19 vaccine hesitancy: evidence from global dyadic survey. Soc Sci Med 2022;311:115346 [FREE Full text] [doi: 10.1016/j.socscimed.2022.115346] [Medline: 36108562]</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_3hnj97t">COVID-19 vaccine uptake and factors affecting hesitancy among US nurses, March-June 2021</title>
		<author>
			<persName><forename type="first">Rich-Edwards Jw</forename><surname>Rocheleau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hankins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Katuska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Kumph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename></persName>
		</author>
		<idno type="DOI">10.2105/AJPH.2022.307050</idno>
		<idno>Medline: 36223573</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JD97JQe">Am J Public Health</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1620" to="1629" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rich-Edwards JW, Rocheleau CM, Ding M, Hankins JA, Katuska LM, Kumph X, et al. COVID-19 vaccine uptake and factors affecting hesitancy among US nurses, March-June 2021. Am J Public Health 2022;112(11):1620-1629 [doi: 10.2105/AJPH.2022.307050] [Medline: 36223573]</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_6WcpX7g">Factors associated with COVID-19 vaccination among individuals with vaccine hesitancy in French-speaking Belgium</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Gbenonsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Labat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oleffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jidovsteff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Servais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Vermeulen</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamanetworkopen.2022.34433</idno>
		<idno>Medline: 36112379</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7b6FttV">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">2234433</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Gbenonsi GY, Labat A, Oleffe A, Jidovsteff B, Servais O, Vermeulen N, et al. Factors associated with COVID-19 vaccination among individuals with vaccine hesitancy in French-speaking Belgium. JAMA Netw Open 2022;5(9):e2234433 [FREE Full text] [doi: 10.1001/jamanetworkopen.2022.34433] [Medline: 36112379]</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_wbwgJwH">Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents</title>
		<author>
			<persName><forename type="first">M</forename><surname>Caserotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Girardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rubaltelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tasso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gavaruzzi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.socscimed.2021.113688</idno>
		<idno>Medline: 33485215</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_D8Ftwww">Soc Sci Med</title>
		<imprint>
			<biblScope unit="volume">272</biblScope>
			<biblScope unit="page">113688</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Caserotti M, Girardi P, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents. Soc Sci Med 2021;272:113688 [FREE Full text] [doi: 10.1016/j.socscimed.2021.113688] [Medline: 33485215]</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_cCpnDhQ">Medics as a positive deviant in influenza vaccination: the role of vaccine beliefs, self-efficacy and contextual variables</title>
		<author>
			<persName><forename type="first">D</forename><surname>Włodarczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Ziętalewicz</surname></persName>
		</author>
		<idno type="DOI">10.3390/vaccines10050723</idno>
		<idno>Medline: 35632479</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FE89CAU">Vaccines</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">723</biblScope>
			<date type="published" when="2022">2022</date>
			<pubPlace>Basel</pubPlace>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Włodarczyk D, Ziętalewicz U. Medics as a positive deviant in influenza vaccination: the role of vaccine beliefs, self-efficacy and contextual variables. Vaccines (Basel) 2022;10(5):723 [FREE Full text] [doi: 10.3390/vaccines10050723] [Medline: 35632479]</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_jPrP4Mb">COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schwarzinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Arwidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Alla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Luchini</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2468-2667(21)00012-8</idno>
		<idno>Medline: 33556325</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NsNaeSK">Lancet Public Health</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="210" to="e221" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Schwarzinger M, Watson V, Arwidson P, Alla F, Luchini S. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health 2021;6(4):e210-e221 [FREE Full text] [doi: 10.1016/S2468-2667(21)00012-8] [Medline: 33556325]</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_3RMA6u6">Changes in COVID-19 vaccine hesitancy among black and white individuals in the US</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Padamsee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Hovick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Na</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Nisbet</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamanetworkopen.2021.44470</idno>
		<idno>Medline: 35061038</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sKxbAqd">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">2144470</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Padamsee TJ, Bond RM, Dixon GN, Hovick SR, Na K, Nisbet EC, et al. Changes in COVID-19 vaccine hesitancy among black and white individuals in the US. JAMA Netw Open 2022;5(1):e2144470 [FREE Full text] [doi: 10.1001/jamanetworkopen.2021.44470] [Medline: 35061038]</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_7neZAej">COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Salali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Uysal</surname></persName>
		</author>
		<idno type="DOI">10.1017/S0033291720004067</idno>
		<idno>Medline: 33070804</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W8kwDhR">Psychol Med</title>
		<imprint>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Salali GD, Uysal MS. COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. Psychol Med 2020:1-3 [FREE Full text] [doi: 10.1017/S0033291720004067] [Medline: 33070804]</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_CqW7gWF">Coronavirus conspiracy suspicions, general vaccine attitudes, trust and coronavirus information source as predictors of vaccine hesitancy among UK residents during the COVID-19 pandemic</title>
		<author>
			<persName><forename type="first">D</forename><surname>Allington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mcandrew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Moxham-Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Duffy</surname></persName>
		</author>
		<idno type="DOI">10.1017/S0033291721001434</idno>
		<idno>Medline: 33843509</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_p9jNTfq">Psychol Med</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="236" to="247" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Allington D, McAndrew S, Moxham-Hall V, Duffy B. Coronavirus conspiracy suspicions, general vaccine attitudes, trust and coronavirus information source as predictors of vaccine hesitancy among UK residents during the COVID-19 pandemic. Psychol Med 2023;53(1):236-247 [FREE Full text] [doi: 10.1017/S0033291721001434] [Medline: 33843509]</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_7cWJdHB">Vaccine hesitancy&apos; among university students in Italy during the COVID-19 pandemic</title>
		<author>
			<persName><forename type="first">S</forename><surname>Barello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nania</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dellafiore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Graffigna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Caruso</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10654-020-00670-z</idno>
		<idno>Medline: 32761440</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W8fbrjU">Eur J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="781" to="783" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. &apos;Vaccine hesitancy&apos; among university students in Italy during the COVID-19 pandemic. Eur J Epidemiol 2020;35(8):781-783 [FREE Full text] [doi: 10.1007/s10654-020-00670-z] [Medline: 32761440]</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_gmp4vsX">Strategies for addressing vaccine hesitancy within California state prisons in 2021 and beyond</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Garcia-Grossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gransee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Williams</surname></persName>
		</author>
		<idno type="DOI">10.2105/ajph.2022.307042</idno>
		<idno>Medline: 36075008</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7txY9tP">Am J Public Health</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1543" to="1545" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Garcia-Grossman IR, Gransee L, Williams B. Strategies for addressing vaccine hesitancy within California state prisons in 2021 and beyond. Am J Public Health 2022;112(11):1543-1545 [doi: 10.2105/AJPH.2022.307042] [Medline: 36075008]</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_4Zd68hu">Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales</title>
		<author>
			<persName><forename type="first">U</forename><surname>Agrawal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bedston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mccowan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robertson</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(22)01656-7</idno>
		<idno>Medline: 36244382</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kAzS6tZ">Lancet</title>
		<imprint>
			<biblScope unit="volume">400</biblScope>
			<biblScope unit="issue">10360</biblScope>
			<biblScope unit="page" from="1305" to="1320" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet 2022;400(10360):1305-1320 [FREE Full text] [doi: 10.1016/S0140-6736(22)01656-7] [Medline: 36244382]</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
